No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CDNA240517C10000
- 5.30
- +0.15+2.91%
15min DelayClose May 13 15:59 ET
5.60High5.10Low
5.10Open5.15Pre Close14 Volume559 Open Interest10.00Strike Price7.31KTurnover0.00%IV-1.54%PremiumMay 17, 2024Expiry Date4.98Intrinsic Value100Multiplier4DDays to Expiry0.32Time Value100Contract SizeAmericanOptions Type--Delta--Gamma3.15Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Navigating 5 Analyst Ratings For CareDx
Throughout the last three months, 5 analysts have evaluated CareDx (NASDAQ:CDNA), offering a diverse set of opinions from bullish to bearish.The table below summarizes their recent ratings, showcasing
Express News | Raymond James Downgrades CareDx to Market Perform
CareDx Cut to Market Perform by Raymond James Over Valuation
Express News | Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $14
CareDx Is Maintained at Overweight by Stephens & Co.
CareDx Is Maintained at Overweight by Stephens & Co.
CareDx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 18.42% Stephens & Co. $15 → $18 Maintains Overweight 05/09/2024 -1.32% Craig-Hallum → $15 Reite
Comments
Investors may believe CareDx's strong revenue growth is not imminent, leading to a low P/S ratio. Expected future revenue decline could further decrease the P/S ratio, making a significant stock price rise unlikely.
Little Excitement Around CareDx, Inc's (NASDAQ:CDNA) Revenues As Shares Take 28% PoundingDespite a strong price move, CareDx's P/S ratio still trails the industry. The low P/S is due to the forecast for sliding revenue. Without significant change, drastic rise in the stock is unlikely.
$CareDx(CDNA.US$ 4.80 missed and ran 📈👀
$CareDx(CDNA.US$ Check out these highlights! ((. Reported revenue of $67.2 million, an increase of 7% over the second
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
1
Read more